Pyxis Oncology
PYXS
76 hedge funds and large institutions have $101M invested in Pyxis Oncology in 2026 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 24 reducing their positions, and 10 closing their positions.
2,052% more call options, than puts
Call options by funds: $1.66M | Put options by funds: $77K
149% more capital invested
Capital invested by funds: $40.5M → $101M (+$60.6M)
10.03% more ownership
Funds ownership: 43.88% → 53.91% (+10%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 24
3% less funds holding
Funds holding: 78 → 76 (-2)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGI
GordonMD Global Investments
Beverely Hills,
California
|
+$11.3M |
| 2 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$1.47M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$1M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$910K |
| 5 |
BlackRock
New York
|
+$151K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$835K |
| 2 |
Millennium Management
New York
|
-$315K |
| 3 |
LP
Longaeva Partners
Chicago,
Illinois
|
-$286K |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$280K |
| 5 |
Renaissance Technologies
New York
|
-$223K |
PYXS Hedge Fund Activity: Q2 2026 in Review
76 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q2 2026, worth a combined $101M — up 149% from $40.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of PYXS and 9 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 24 added.
The largest buyer was GordonMD Global Investments, adding an estimated $11.3M. The largest seller was 683 Capital Management, cutting an estimated $835K.
- 76 institutional investors held Pyxis Oncology (PYXS) as of Q2 2026, down from 78 in Q1 2026.
- Funds reported $101M of Pyxis Oncology stock for Q2 2026, up 149% quarter-over-quarter.
- 9 funds opened new Pyxis Oncology positions in Q2 2026 and 10 closed out, a net change of -1 holder.
- The largest Pyxis Oncology buyer in Q2 2026 was GordonMD Global Investments, an estimated $11.3M added.
- The largest Pyxis Oncology seller in Q2 2026 was 683 Capital Management, an estimated $835K sold.
Based on aggregated 13F filings for Q2 2026.